When regulators accept a marketing application, it’s not approval—but it’s a signal. And for Norway-based Photocure ASA and its China-based partner Asieris Pharmaceuticals, that signal just came from Europe.

Asieris announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for Cevira (APL-1702), a drug-device combination therapy designed to treat high-grade squamous intraepithelial lesions (HSIL) of the cervix. The milestone clears the application for formal review, moving the product one step closer to potential commercialization in the EU.

For Photocure, listed on the Oslo Stock Exchange under PHO, the development underscores the global expansion potential of a technology platform long associated with photodynamic therapy in oncology. For Asieris, it marks a pivotal regulatory inflection point in Europe.

A Drug-Device Combo Aimed at Avoiding Surgery

Cevira (APL-1702) is positioned as a first-in-class photodynamic therapy for the non-surgical treatment of HSIL, a precancerous condition often linked to persistent high-risk HPV infection. HSIL is typically treated through surgical excision procedures such as LEEP or conization, which, while effective, can carry risks including bleeding, infection, and potential impacts on future fertility.

Cevira aims to change that equation.

As described by Asieris, the therapy combines hexaminolevulinate hydrochloride ointment with a disposable cervical light applicator. The integrated system delivers localized drug administration followed by activation via an intra-cavity cold light source. The result is targeted photodynamic destruction of abnormal cells while preserving surrounding healthy tissue.

In other words, it’s not just a drug. It’s a tightly engineered drug-device system designed to deliver precision therapy directly to the cervix without surgical intervention.

If approved, it could represent a meaningful shift in the standard of care—particularly for women seeking fertility-preserving options.

Backed by Phase III Data With European Representation

The EMA filing is primarily supported by data from an international, multicenter Phase III clinical trial of APL-1702. Notably, more than 20% of enrolled patients were from Europe, a detail that may strengthen the regulatory case by ensuring regionally relevant clinical representation.

While acceptance of the MAA does not imply approval, it confirms that regulators consider the submission sufficiently complete to begin formal evaluation. The EMA will now assess the therapy’s safety, efficacy, and quality data before issuing an opinion.

Given the complexity of drug-device combination products, regulatory review can be more involved than for small-molecule drugs alone. But successful navigation would position Cevira as one of the few non-surgical therapies approved for HSIL in Europe.

Photodynamic Therapy Expands Beyond Bladder Cancer

Photocure has built its reputation around hexaminolevulinate-based photodynamic diagnostics and therapeutics, particularly in bladder cancer. Licensing Cevira to Asieris for development in cervical precancer broadens the platform’s clinical footprint.

The move also reflects a broader industry push toward organ-preserving, minimally invasive oncology treatments. As biopharma increasingly targets earlier-stage disease and precancerous conditions, therapies that reduce surgical burden and improve quality of life are drawing investor and regulatory interest.

For Photocure, the partnership model allows it to leverage its core technology while offloading development and commercialization risk in specific geographies. For Asieris, which is listed on the Shanghai Stock Exchange (688176), the European filing signals ambitions beyond the domestic Chinese market.

Competitive and Market Implications

HSIL represents a significant global health concern, particularly in regions with established cervical cancer screening programs. While HPV vaccination programs are expanding, millions of women continue to require treatment for high-grade lesions detected through screening.

Currently, surgical excision remains the dominant intervention. A non-surgical, office-based therapy that demonstrates comparable efficacy could reshape treatment algorithms—particularly in younger patients.

However, market adoption would hinge on several factors:

• Comparative efficacy versus standard excision procedures

• Recurrence rates over long-term follow-up

• Ease of integration into gynecological practice

• Reimbursement positioning across EU member states

If EMA review concludes positively, Cevira would enter a European market that is increasingly open to device-enabled combination therapies but also highly cost-conscious.

What Comes Next

With the MAA now accepted, the timeline shifts to regulatory review. The EMA’s Committee for Medicinal Products for Human Use (CHMP) will evaluate the application and eventually issue a recommendation. Final approval would then be granted by the European Commission.

For Photocure and Asieris, this phase represents both scrutiny and opportunity.

An approval would validate the clinical program and potentially establish Cevira as the first-in-class photodynamic therapy for HSIL in Europe. A rejection or request for additional data, while not uncommon, could delay commercialization plans.

For now, acceptance of the filing signals that regulators are ready to take a close look at a therapy that aims to reduce reliance on surgery for cervical precancer.

In oncology—and increasingly in women’s health—the future may not just be about treating disease. It may be about treating it earlier, less invasively, and with more precision.

Get in touch with our MarTech Experts.